|56.73||-0.4900||-0.86%||Vol 11.56M||1Y Perf -19.65%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||0.12 0.21%|
|Target Price||80.08||Analyst Rating||Moderate Buy 2.29|
|Potential %||41.16||Finscreener Ranking||★ 41.35|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 45.27|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★+ 55.74|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★★★ 44.46|
|Price Range Ratio 52W %||-1.60||Earnings Rating||Sell|
|Market Cap||118.51B||Earnings Date||26th Oct 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||26th Oct 2023|
|Estimated EPS Next Report||1.80|
|EPS Growth Next 5 Years %||5.10|
|Avg. Weekly Volume||9.84M|
|Avg. Monthly Volume||10.96M|
|Avg. Quarterly Volume||10.02M|
Bristol-Myers Squibb Company (NYSE: BMY) stock closed at 56.73 per share at the end of the most recent trading day (a -0.86% change compared to the prior day closing price) with a volume of 11.56M shares and market capitalization of 118.51B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 30250 people. Bristol-Myers Squibb Company CEO is Giovanni Caforio.
The one-year performance of Bristol-Myers Squibb Company stock is -19.65%, while year-to-date (YTD) performance is -21.15%. BMY stock has a five-year performance of -9.1%. Its 52-week range is between 57.12 and 81.435, which gives BMY stock a 52-week price range ratio of -1.60%
Bristol-Myers Squibb Company currently has a PE ratio of 23.80, a price-to-book (PB) ratio of 4.75, a price-to-sale (PS) ratio of 4.34, a price to cashflow ratio of 11.50, a PEG ratio of 4.67, a ROA of 6.95%, a ROC of 9.97% and a ROE of 20.80%. The company’s profit margin is 12.43%, its EBITDA margin is 41.30%, and its revenue ttm is $34.75 Billion , which makes it $16.35 revenue per share.
Of the last four earnings reports from Bristol-Myers Squibb Company, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.80 for the next earnings report. Bristol-Myers Squibb Company’s next earnings report date is 26th Oct 2023.
The consensus rating of Wall Street analysts for Bristol-Myers Squibb Company is Moderate Buy (2.29), with a target price of $80.08, which is +41.16% compared to the current price. The earnings rating for Bristol-Myers Squibb Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bristol-Myers Squibb Company has a dividend yield of 3.21% with a dividend per share of $2.28 and a payout ratio of 273.00%.
Bristol-Myers Squibb Company has a Sell technical analysis rating based on Technical Indicators (ADX : 5.01, ATR14 : 0.89, CCI20 : -140.21, Chaikin Money Flow : -0.40, MACD : -0.92, Money Flow Index : 29.70, ROC : -3.07, RSI : 29.75, STOCH (14,3) : 2.92, STOCH RSI : 0.00, UO : 37.06, Williams %R : -97.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bristol-Myers Squibb Company in the last 12-months were: Adam Lenkowsky (Option Excercise at a value of $0), Ann Powell Judge (Option Excercise at a value of $0), Ann Powell Judge (Sold 11 183 shares of value $835 258 ), Boerner Christopher (Option Excercise at a value of $0), Caforio Giovanni (Option Excercise at a value of $0), Caforio Giovanni (Sold 240 000 shares of value $17 916 000 ), Christopher S. Boerner (Option Excercise at a value of $0), David V. Elkins (Option Excercise at a value of $0), Elizabeth A. Mily (Option Excercise at a value of $0), Elizabeth Mily (Option Excercise at a value of $0), Giovanni Caforio (Option Excercise at a value of $0), Giovanni Caforio (Sold 240 000 shares of value $17 916 000 ), Gregory Scott Meyers (Sold 0 shares of value $0 ), Karin Shanahan (Sold 0 shares of value $0 ), Leung Sandra (Option Excercise at a value of $0), Michelle Weese (Option Excercise at a value of $0), Powell Ann Judge (Option Excercise at a value of $0), Powell Ann Judge (Sold 27 433 shares of value $2 142 570 ), Rupert Vessey (Option Excercise at a value of $4 643 869), Rupert Vessey (Sold 142 205 shares of value $10 621 578 ), Samit Hirawat (Option Excercise at a value of $0), Sandra Leung (Option Excercise at a value of $0), Sharon Greenlees (Sold 0 shares of value $0 )
Mon, 10 Jul 2023 10:45 GMT Bristol Myers (BMY) Has a New Rating from SVB Securities- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.